Published in Cancer Res on January 12, 2010
Molecular mechanisms of cancer development in obesity. Nat Rev Cancer (2011) 3.65
Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci U S A (2010) 3.16
Cellular metabolic stress: considering how cells respond to nutrient excess. Mol Cell (2010) 2.50
Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol (2010) 2.26
Obesity and cancer risk: evidence, mechanisms, and recommendations. Ann N Y Acad Sci (2012) 2.04
Insulin-like growth factor receptor inhibitors: baby or the bathwater? J Natl Cancer Inst (2012) 1.86
The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab (2010) 1.67
Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol (2010) 1.61
A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res (2011) 1.53
The link between the metabolic syndrome and cancer. Int J Biol Sci (2011) 1.37
Diabetes and breast cancer risk: a meta-analysis. Br J Cancer (2012) 1.30
Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol (2013) 1.29
Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. Diabetes (2009) 1.28
Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model. Oncogene (2012) 1.17
Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality. Physiol Rev (2015) 1.03
Energy-preserving effects of IGF-1 antagonize starvation-induced cardiac autophagy. Cardiovasc Res (2011) 1.03
Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-I receptor. Diabetes (2013) 1.01
Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Res (2012) 1.01
Diabetes and cancer: Associations, mechanisms, and implications for medical practice. World J Diabetes (2014) 1.01
Transcription factor ATF3 links host adaptive response to breast cancer metastasis. J Clin Invest (2013) 1.00
Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer. Diabetes Care (2013) 1.00
The insulin receptor: a new target for cancer therapy. Front Endocrinol (Lausanne) (2011) 0.99
Opposing functions of Akt isoforms in lung tumor initiation and progression. PLoS One (2014) 0.99
Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes. Endocr Relat Cancer (2010) 0.98
Diabetic angiopathy and angiogenic defects. Fibrogenesis Tissue Repair (2012) 0.96
The effect Akt2 deletion on tumor development in Pten(+/-) mice. Oncogene (2011) 0.96
No association of risk variants for diabetes and obesity with breast cancer: the Multiethnic Cohort and PAGE studies. Cancer Epidemiol Biomarkers Prev (2011) 0.93
Redefining the impact of nutrition on breast cancer incidence: is epigenetics involved? Nutr Res Rev (2012) 0.93
Extranuclear estrogen receptor's roles in physiology: lessons from mouse models. Am J Physiol Endocrinol Metab (2014) 0.93
A twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factors. Int J Endocrinol (2013) 0.93
Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor. Breast Cancer Res Treat (2011) 0.93
Quantifying insulin receptor isoform expression in FFPE breast tumors. Growth Horm IGF Res (2012) 0.93
Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer. Clin Cancer Res (2015) 0.92
Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling. Crit Rev Oncog (2012) 0.92
CD24(+) cells fuel rapid tumor growth and display high metastatic capacity. Breast Cancer Res (2015) 0.92
Elevated circulating IGF-I promotes mammary gland development and proliferation. Endocrinology (2010) 0.91
Highly specific role of the insulin receptor in breast cancer progression. Endocr Relat Cancer (2015) 0.90
Abdominal obesity, independent from caloric intake, accounts for the development of intestinal tumors in Apc(1638N/+) female mice. Cancer Prev Res (Phila) (2013) 0.88
Effect of elevated basal insulin on cancer incidence and mortality in cancer incident patients: the Israel GOH 29-year follow-up study. Diabetes Care (2012) 0.86
Serum Lipids and the Risk of Gastrointestinal Malignancies in the Swedish AMORIS Study. J Cancer Epidemiol (2012) 0.86
The Warburg effect revisited--lesson from the Sertoli cell. Med Res Rev (2014) 0.86
Use of glucocorticoids and risk of breast cancer: a Danish population-based case-control study. Breast Cancer Res (2012) 0.86
Targeting IGF-1R: at a crossroad. Oncology (Williston Park) (2011) 0.85
The association between type 2 diabetes mellitus and women cancer: the epidemiological evidences and putative mechanisms. Biomed Res Int (2015) 0.85
Serum glucose and fructosamine in relation to risk of cancer. PLoS One (2013) 0.85
Estrogen modulates metabolic pathway adaptation to available glucose in breast cancer cells. Mol Endocrinol (2012) 0.85
Diet-induced metabolic change induces estrogen-independent allometric mammary growth. Proc Natl Acad Sci U S A (2012) 0.85
Treatment with insulin analog X10 and IGF-1 increases growth of colon cancer allografts. PLoS One (2013) 0.85
Examining the relationship between diet-induced acidosis and cancer. Nutr Metab (Lond) (2012) 0.84
Hyperinsulinemia promotes metastasis to the lung in a mouse model of Her2-mediated breast cancer. Endocr Relat Cancer (2013) 0.84
Oncogene activation induces metabolic transformation resulting in insulin-independence in human breast cancer cells. PLoS One (2011) 0.84
The p85 regulatory subunit of PI3K mediates cAMP-PKA and insulin biological effects on MCF-7 cell growth and motility. ScientificWorldJournal (2014) 0.83
Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia. Oncogene (2011) 0.83
A tale of two receptors: insulin and insulin-like growth factor signaling in cancer. Clin Cancer Res (2014) 0.83
The Tumor Macroenvironment: Cancer-Promoting Networks Beyond Tumor Beds. Adv Cancer Res (2015) 0.83
Analysis of the quantitative balance between insulin-like growth factor (IGF)-1 ligand, receptor, and binding protein levels to predict cell sensitivity and therapeutic efficacy. BMC Syst Biol (2014) 0.82
Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions. Cancer Discov (2016) 0.82
Novel Aspects Concerning the Functional Cross-Talk between the Insulin/IGF-I System and Estrogen Signaling in Cancer Cells. Front Endocrinol (Lausanne) (2015) 0.81
IGF-I induces upregulation of DDR1 collagen receptor in breast cancer cells by suppressing MIR-199a-5p through the PI3K/AKT pathway. Oncotarget (2016) 0.81
The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link. Front Endocrinol (Lausanne) (2015) 0.80
Insulin/Insulin-like growth factors in cancer: new roles for the aryl hydrocarbon receptor, tumor resistance mechanisms, and new blocking strategies. Front Endocrinol (Lausanne) (2015) 0.80
Reduced signaling of PI3K-Akt and RAS-MAPK pathways is the key target for weight-loss-induced cancer prevention by dietary calorie restriction and/or physical activity. J Nutr Biochem (2014) 0.80
Obesity and cancer, a case for insulin signaling. Cell Death Dis (2015) 0.79
Novel cross talk between IGF-IR and DDR1 regulates IGF-IR trafficking, signaling and biological responses. Oncotarget (2015) 0.79
Obesity and Breast Cancer: Molecular Interconnections and Potential Clinical Applications. Oncologist (2016) 0.79
The Novel Functions of High-Molecular-Mass Complexes Containing Insulin Receptor Substrates in Mediation and Modulation of Insulin-Like Activities: Emerging Concept of Diverse Functions by IRS-Associated Proteins. Front Endocrinol (Lausanne) (2015) 0.79
Cancer biology in diabetes. J Diabetes Investig (2014) 0.79
Nuclear receptors outside the nucleus: extranuclear signalling by steroid receptors. Nat Rev Mol Cell Biol (2016) 0.78
Stimulatory actions of IGF-I are mediated by IGF-IR cross-talk with GPER and DDR1 in mesothelioma and lung cancer cells. Oncotarget (2016) 0.78
Metabolic serum biomarkers for the prediction of cancer: a follow-up of the studies conducted in the Swedish AMORIS study. Ecancermedicalscience (2015) 0.77
Mammary gland development-It's not just about estrogen. J Dairy Sci (2015) 0.76
Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index. Cancer Prev Res (Phila) (2017) 0.76
Ovariectomy is associated with metabolic impairments and enhanced mammary tumor growth in MKR mice. J Endocrinol (2015) 0.76
The association between adult attained height and sitting height with mortality in the European Prospective Investigation into Cancer and Nutrition (EPIC). PLoS One (2017) 0.75
Should diabetic women with breast cancer have their own intervention studies? Endocr Relat Cancer (2012) 0.75
Non-metabolisable insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes. Diabetologia (2016) 0.75
Diabetes mellitus and prognosis in women with breast cancer: A systematic review and meta-analysis. Medicine (Baltimore) (2016) 0.75
Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin Receptor. Mol Cancer Res (2015) 0.75
Metabolic syndrome and pre-diabetes contribute to racial disparities in breast cancer outcomes: hypothesis and proposed pathways. Diabetes Metab Res Rev (2016) 0.75
Silencing vimentin expression decreases pulmonary metastases in a pre-diabetic mouse model of mammary tumor progression. Oncogene (2016) 0.75
EMT reversal in human cancer cells after IR knockdown in hyperinsulinemic mice. Endocr Relat Cancer (2016) 0.75
Diabetes, Epstein-Barr virus and extranodal natural killer/T-cell lymphoma in India: Unravelling the plausible nexus. Indian J Med Paediatr Oncol (2016) 0.75
Social disparities, health risk behaviors, and cancer. BMC Surg (2013) 0.75
Carcinogenic effects of oil dispersants: A KEGG pathway-based RNA-seq study of human airway epithelial cells. Gene (2016) 0.75
Effects of insulin on human pancreatic cancer progression modeled in vitro. BMC Cancer (2014) 0.75
Heparanase augments insulin receptor signaling in breast carcinoma. Oncotarget (2016) 0.75
Mutant p53 potentiates the oncogenic effects of insulin by inhibiting the tumor suppressor DAB2IP. Proc Natl Acad Sci U S A (2017) 0.75
Insulin resistance in vascular endothelial cells promotes intestinal tumour formation. Oncogene (2017) 0.75
Activating Transcription Factor-5 Knockdown Reduces Aggressiveness of Mammary Tumor Cells and Attenuates Mammary Tumor Growth. Front Endocrinol (Lausanne) (2017) 0.75
Discoidin domain receptor 1 modulates insulin receptor signaling and biological responses in breast cancer cells. Oncotarget (2017) 0.75
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med (2003) 35.39
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet (2008) 20.62
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer (2004) 16.69
Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol (1992) 12.96
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res (2005) 8.98
Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol (2003) 8.61
Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer (2007) 5.57
Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA (2008) 4.48
Overweight, obesity, and cancer risk. Lancet Oncol (2002) 4.44
Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst (2008) 3.73
Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev (1995) 3.58
Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr (2007) 3.27
Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res (2007) 3.13
Signaling pathways in mammary gland development. Dev Cell (2001) 3.10
Akt1 governs breast cancer progression in vivo. Proc Natl Acad Sci U S A (2007) 2.67
Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc Natl Acad Sci U S A (2006) 2.59
Syngeneic mouse mammary carcinoma cell lines: two closely related cell lines with divergent metastatic behavior. Clin Exp Metastasis (2005) 2.52
Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev (2004) 2.40
Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res (2008) 2.37
The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem (2008) 2.20
Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev (2001) 2.18
Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev (2007) 1.99
The insulin-related ovarian regulatory system in health and disease. Endocr Rev (1999) 1.90
Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia (2008) 1.63
Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol Reprod (1998) 1.47
The role of endocrine insulin-like growth factor-I and insulin in breast cancer. J Mammary Gland Biol Neoplasia (2008) 1.40
Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev (2008) 1.38
Isoform-specific requirement for Akt1 in the developmental regulation of cellular metabolism during lactation. Cell Metab (2006) 1.36
Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Res (1972) 1.35
Influence of insulin administration on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in intact, oophorectomized, and hypophysectomized rats. Cancer Res (1972) 1.27
Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. J Med Chem (2005) 1.22
PTEN overexpression suppresses proliferation and differentiation and enhances apoptosis of the mouse mammary epithelium. J Clin Invest (2002) 1.16
Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice. J Natl Cancer Inst (1981) 1.13
Insulin stimulates the clonogenic potential of angiogenic endothelial progenitor cells by IGF-1 receptor-dependent signaling. Mol Med (2008) 1.11
Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Physicians (1997) 1.08
The insulin-like growth factors (IGFs) and IGF binding proteins in postnatal development of murine mammary glands. J Mammary Gland Biol Neoplasia (2000) 1.08
Accelerated tumor formation in a fatless mouse with type 2 diabetes and inflammation. Cancer Res (2006) 1.06
Overexpression of the tumor suppressor gene phosphatase and tensin homologue partially inhibits wnt-1-induced mammary tumorigenesis. Cancer Res (2005) 1.02
Hepatocellular neoplasms induced by low-number pancreatic islet transplants in streptozotocin diabetic rats. Am J Pathol (1997) 1.01
Insulin regulates insulin-like growth factor I mRNA in rat hepatocytes. Am J Physiol (1991) 1.00
Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse. In Vitro Cell Dev Biol Anim (2002) 0.94
The insulin receptor is essential for virus-induced tumorigenesis of Kaposi's sarcoma. Oncogene (2006) 0.87
Influence of insulin on growth and metabolism of 7,12-dimethylbenz(alpha)anthracene-induced mammary tumors. Cancer Res (1974) 0.86
High-affinity insulin binding to an atypical insulin-like growth factor-I receptor in human breast cancer cells. J Clin Invest (1992) 0.83
The insulin receptor content is increased in breast cancers initiated by three different oncogenes in transgenic mice. Breast Cancer Res Treat (1997) 0.81
Insulin dependence of murine T-cell lymphoma. II. Insulin-deficient diabetic mice and mice fed low-energy diet develop resistance to lymphoma growth. Int J Cancer (1993) 0.80
The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev (2006) 4.93
Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest (2002) 3.86
Tumor-induced osteomalacia. Endocr Relat Cancer (2011) 3.13
Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. Cancer Prev Res (Phila) (2009) 2.91
Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma. Nat Genet (2009) 2.58
Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells (2005) 2.52
Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med (2004) 2.51
Minireview: IGF, Insulin, and Cancer. Endocrinology (2011) 2.16
Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res (2005) 2.07
Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest (2006) 2.03
Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab (2007) 2.02
mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis. Cell Stem Cell (2012) 1.99
Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res (2002) 1.96
The worldwide diabetes epidemic. Curr Opin Endocrinol Diabetes Obes (2012) 1.86
Activation of the mammalian target of rapamycin (mTOR) is essential for oligodendrocyte differentiation. J Neurosci (2009) 1.86
Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res (2004) 1.83
Proteomic analysis of laser-captured paraffin-embedded tissues: a molecular portrait of head and neck cancer progression. Clin Cancer Res (2008) 1.83
Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest (2004) 1.82
The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res (2009) 1.78
Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res (2009) 1.72
Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro. Cancer Res (2009) 1.71
Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus. Endocrinology (2006) 1.71
The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab (2010) 1.67
Protein kinase B/Akt binds and phosphorylates PED/PEA-15, stabilizing its antiapoptotic action. Mol Cell Biol (2003) 1.67
BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther (2009) 1.62
Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. Cancer Res (2011) 1.54
Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate (2010) 1.54
Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis. J Hepatol (2013) 1.52
Conditional expression of K-ras in an epithelial compartment that includes the stem cells is sufficient to promote squamous cell carcinogenesis. Cancer Res (2004) 1.50
Obesity, type 2 diabetes, and cancer: the insulin and IGF connection. Endocr Relat Cancer (2012) 1.48
A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells. Sci Signal (2011) 1.45
The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes. Diabetes Metab Res Rev (2014) 1.45
Increased tumor growth in mice with diet-induced obesity: impact of ovarian hormones. Endocrinology (2006) 1.44
Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res (2003) 1.44
Intracellular collagen degradation mediated by uPARAP/Endo180 is a major pathway of extracellular matrix turnover during malignancy. J Cell Biol (2005) 1.42
HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther (2008) 1.40
The role of endocrine insulin-like growth factor-I and insulin in breast cancer. J Mammary Gland Biol Neoplasia (2008) 1.40
Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions. Endocr Rev (2008) 1.38
The link between the metabolic syndrome and cancer. Int J Biol Sci (2011) 1.37
Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res (2009) 1.37
Disruption of steroid and prolactin receptor patterning in the mammary gland correlates with a block in lobuloalveolar development. Mol Endocrinol (2002) 1.37
Pancreatic-specific inactivation of IGF-I gene causes enlarged pancreatic islets and significant resistance to diabetes. Diabetes (2004) 1.36
Biological effects of growth hormone on carbohydrate and lipid metabolism. Growth Horm IGF Res (2009) 1.35
In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res (2006) 1.34
Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann N Y Acad Sci (2011) 1.34
Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy. Mol Endocrinol (2008) 1.33
Insulin resistance as the underlying cause for the metabolic syndrome. Med Clin North Am (2007) 1.29
Serum IGF-1 determines skeletal strength by regulating subperiosteal expansion and trait interactions. J Bone Miner Res (2009) 1.29
Leptin improves insulin resistance and hyperglycemia in a mouse model of type 2 diabetes. Endocrinology (2005) 1.29
Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. Diabetes (2009) 1.28
Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes (2003) 1.28
Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjögren's syndrome. Hum Gene Ther (2003) 1.28
PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene (2004) 1.27
Insulin-like growth factor 1 receptor signaling regulates skin development and inhibits skin keratinocyte differentiation. Mol Cell Biol (2006) 1.26
Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage. J Biol Chem (2002) 1.26
Insulin-like growth factor type-I receptor internalization and recycling mediate the sustained phosphorylation of Akt. J Biol Chem (2007) 1.26
Denosumab treatment for fibrous dysplasia. J Bone Miner Res (2012) 1.26
Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells. Mol Cell Biol (2005) 1.25
Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism. FASEB J (2008) 1.23
Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. Cancer Res (2010) 1.22
Increased P85alpha is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess. J Biol Chem (2005) 1.22
The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. BMC Cell Biol (2008) 1.21
Elevated levels of insulin-like growth factor (IGF)-I in serum rescue the severe growth retardation of IGF-I null mice. Endocrinology (2009) 1.21
Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanoma. Pigment Cell Melanoma Res (2013) 1.20
Growth hormone regulates the balance between bone formation and bone marrow adiposity. J Bone Miner Res (2010) 1.20
High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res (2010) 1.20
Targeted loss of GHR signaling in mouse skeletal muscle protects against high-fat diet-induced metabolic deterioration. Diabetes (2012) 1.18
Mammalian target of rapamycin promotes oligodendrocyte differentiation, initiation and extent of CNS myelination. J Neurosci (2014) 1.18
TDAG51 mediates the effects of insulin-like growth factor I (IGF-I) on cell survival. J Biol Chem (2004) 1.17
Global gene expression profile of nasopharyngeal carcinoma by laser capture microdissection and complementary DNA microarrays. Clin Cancer Res (2004) 1.17
PTEN overexpression suppresses proliferation and differentiation and enhances apoptosis of the mouse mammary epithelium. J Clin Invest (2002) 1.16
Type 2 diabetes and cancer: what is the connection? Mt Sinai J Med (2010) 1.16
Absence of the full-length breast cancer-associated gene-1 leads to increased expression of insulin-like growth factor signaling axis members. Cancer Res (2006) 1.15